These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27824831)

  • 1. Myriad's impact on gene patents.
    Aboy M; Liddell K; Liddicoat J; Crespo C
    Nat Biotechnol; 2016 Nov; 34(11):1119-1123. PubMed ID: 27824831
    [No Abstract]   [Full Text] [Related]  

  • 2. Intellectual property. Drug patents at the Supreme Court.
    Hemphill CS; Sampat B
    Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
    [No Abstract]   [Full Text] [Related]  

  • 3. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequenom, the U.S. Supreme Court, and Personalized Medicine.
    Kodroff CA
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):49-52. PubMed ID: 27267566
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.
    Offit K; Bradbury A; Storm C; Merz JF; Noonan KE; Spence R
    J Clin Oncol; 2013 Jul; 31(21):2743-8. PubMed ID: 23766521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Not quite a myriad of gene patents.
    Graff GD; Phillips D; Lei Z; Oh S; Nottenburg C; Pardey PG
    Nat Biotechnol; 2013 May; 31(5):404-10. PubMed ID: 23657391
    [No Abstract]   [Full Text] [Related]  

  • 7. Take off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
    Bergin C
    Am Univ Law Rev; 2013; 63(1):173-217. PubMed ID: 25335200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 9. Supreme Court to decide whether payments by patent holders to delay production of generics are anticompetitive.
    Roehr B
    BMJ; 2012 Dec; 345():e8464. PubMed ID: 23236054
    [No Abstract]   [Full Text] [Related]  

  • 10. The changing life science patent landscape.
    Rai AK; Sherkow JS
    Nat Biotechnol; 2016 Mar; 34(3):292-4. PubMed ID: 26963552
    [No Abstract]   [Full Text] [Related]  

  • 11. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 12. Justices expand rights to experiment with patented drugs.
    Pollack A
    N Y Times Web; 2005 Jun; ():C1, C8. PubMed ID: 15966121
    [No Abstract]   [Full Text] [Related]  

  • 13. Myriad diversifies, fights rearguard action on patents.
    Allison M
    Nat Biotechnol; 2014 Mar; 32(3):211. PubMed ID: 24727763
    [No Abstract]   [Full Text] [Related]  

  • 14. Muddying the waters: how the Supreme Court's decision in Merck v. Integra fails to resolve problems of judicial interpretation of 35 U.S.C. Section 271(E)(1), the "safe harbor" provision of the Hatch-Waxman Act.
    Sertic M
    Health Matrix Clevel; 2007; 17(2):377-439. PubMed ID: 18326397
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
    Furrow ME
    Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
    [No Abstract]   [Full Text] [Related]  

  • 16. Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?
    Chandrasekharan S; McGuire AL; Van den Veyver IB
    Prenat Diagn; 2014 Oct; 34(10):921-6. PubMed ID: 24989832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA patent decision leaves questions for diagnostics.
    Harrison C
    Nat Rev Drug Discov; 2011 Aug; 10(9):650-1. PubMed ID: 21878971
    [No Abstract]   [Full Text] [Related]  

  • 18. The History of Patenting Genetic Material.
    Sherkow JS; Greely HT
    Annu Rev Genet; 2015; 49():161-82. PubMed ID: 26442843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patent watch: Australian court upholds Myriad's gene patent.
    Harrison C
    Nat Rev Drug Discov; 2014 Nov; 13(11):805. PubMed ID: 25359373
    [No Abstract]   [Full Text] [Related]  

  • 20. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.